Ernst Geutjes

As a biotechnology entrepreneur and investment professional, Ernst specializes in oncology drug development and venture creation. Ernst works with oncology biotechs, investors and venture creators as consultant or EiR/CxO. Ernst has held key roles, including EiR/CxO at Sapreme Technologies, Neohla Bioscience, Flindr Therapeutics (20 million Series A, 2024) and Inthera Bioscience.

He was a partner with Aglaia Oncology Funds, a boutique venture capital firm that is specialized in early-stage oncology therapeutics investments and venture creation (i.e Merus). Ernst developed this entrepreneurial spirit in his academic life working in the laboratory of Hidde Ploegh at Harvard Medical School and at the translational cancer research group of Prof. Rene Bernards at the Netherlands Cancer Institute.

‍